BC055324 Inhibitors
BC055324, a protein of growing interest, is implicated in cellular processes associated with proliferation, survival, and transcriptional regulation. While its precise function is still under investigation, BC055324's involvement in critical signaling pathways underscores its significance in cellular physiology. BC055324 inhibitors, represented by diverse compounds, offer insights into potential regulatory mechanisms. Dasatinib, a BCR-ABL and Src kinase inhibitor, may influence BC055324 indirectly by targeting key kinases involved in proliferation and survival pathways. Additionally, Rapamycin and AZD8055, mTOR inhibitors, disrupt the mTOR pathway, impacting BC055324 expression and function in the context of cell growth and proliferation. EGFR inhibitors, including Gefitinib, modulate the EGFR pathway, potentially influencing BC055324 indirectly and altering cellular processes related to transcriptional regulation and cell growth. MEK inhibitors such as Trametinib, U0126, and PD0325901 target the MAPK/ERK pathway, suggesting a role in BC055324 modulation within the context of cellular growth and differentiation.
Furthermore, p38 MAPK inhibitor SB202190 and PI3K inhibitors Wortmannin and LY294002 affect specific signaling pathways, potentially influencing BC055324 expression and function. Multi-kinase inhibitors Sorafenib and Imatinib offer additional avenues for exploring BC055324 regulation through their impacts on various kinases associated with proliferation and survival. In conclusion, BC055324 inhibitors serve as valuable tools for dissecting the functional significance of this protein in cellular processes. The diverse mechanisms of inhibition, targeting multiple signaling pathways, contribute to a nuanced understanding of the intricate molecular networks that converge on BC055324. Continued research into the precise functions of BC055324 and the effects of these inhibitors will undoubtedly provide deeper insights into the regulatory landscape governing cellular proliferation and survival.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
BCR-ABL and Src family kinase inhibitor. Dasatinib targets BCR-ABL and Src kinases, potentially influencing BC055324 indirectly. This interference may impact BC055324 expression and function, altering cellular processes associated with proliferation and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor. Rapamycin disrupts the mTOR pathway, which crosstalks with BC055324 signaling. This interference may influence BC055324 expression and function, impacting cellular processes associated with cell growth and proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFR inhibitor. Gefitinib targets the EGFR pathway, potentially influencing BC055324 indirectly. This interference may impact BC055324 expression and function, altering cellular processes associated with transcriptional regulation and cell growth. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor targeting the MAPK/ERK pathway. Trametinib disrupts the MAPK/ERK pathway, potentially affecting BC055324 expression and function in the context of cellular growth and differentiation. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
p38 MAPK inhibitor. SB202190 influences the p38 MAPK pathway, potentially modulating BC055324 expression and function in specific cellular contexts. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
mTOR inhibitor. AZD8055 disrupts the mTOR pathway, which crosstalks with BC055324 signaling. This interference may influence BC055324 expression and function, impacting cellular processes associated with cell growth and proliferation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor. Wortmannin disrupts the PI3K/Akt pathway, which crosstalks with BC055324 signaling. This interference may influence BC055324 expression and function, impacting cellular processes associated with transcriptional regulation and cell growth. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor targeting the PI3K/Akt pathway. LY294002 disrupts the PI3K/Akt pathway, which crosstalks with BC055324 signaling. This interference may influence BC055324 expression and function, impacting cellular processes associated with transcriptional regulation and cell growth. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Multi-kinase inhibitor. Sorafenib targets RAF, VEGFR, and PDGFR, potentially influencing BC055324 indirectly. This interference may impact BC055324 expression and function, altering cellular processes associated with proliferation and survival. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
BCR-ABL and c-Kit inhibitor. Imatinib targets BCR-ABL and c-Kit, potentially influencing BC055324 indirectly. This interference may impact BC055324 expression and function, altering cellular processes associated with proliferation and survival. | ||||||